The B-cell response to a primary and booster course of MenACWY-CRM197vaccine administered at 2, 4 and 12 months of age
A quadrivalent meningococcal vaccine conjugated to CRM197(MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197in children. At 5 months of age, following primary immunisation, serogroup-specific memo...
Gespeichert in:
| Veröffentlicht in: | Vaccine 2013-05, Vol.31 (20), p.2441 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | 20 |
| container_start_page | 2441 |
| container_title | Vaccine |
| container_volume | 31 |
| creator | Blanchard-Rohner, Geraldine Snape, Matthew D Kelly, Dominic F O'Connor, Daniel John, Tessa Clutterbuck, Elizabeth A Ohene-Kena, Brigitte Klinger, Chaam L Odrljin, Tatjana Pollard, Andrew J |
| description | A quadrivalent meningococcal vaccine conjugated to CRM197(MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197in children. At 5 months of age, following primary immunisation, serogroup-specific memory B-cells were detectable in fewer than 25% of children, although protective antibody titres (hSBA>=4) were detectable in 69% of children against serogroup A and more than 95% against the other serogroups. At 12 months, before booster immunisation the percentages with hSBA>=4 were 5% for serogroup A, and between 44 and 70% for the other serogroups. One month after booster immunisation with MenACWY-CRM197over 50% of children had detectable memory B-cells, and 91% had hSBA>=4 against serogroup A and more than 99% against the other serogroups. These data show that few antigen-specific anticapsular memory B-cells can be detected after two-doses priming with MenACWY-CRM197. For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p |
| doi_str_mv | 10.1016/j.vaccine.2013.03.036 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_1668004015</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3641865291</sourcerecordid><originalsourceid>FETCH-proquest_journals_16680040153</originalsourceid><addsrcrecordid>eNqNjU9LxDAUxIMoWP98BOGBV1PfS9ts96hF8bIXWVBPS2zfui1tUpPsgt_eVvYDCANzmN_MCHFDmBKSvu_Sg6nr1nKqkLIUZ-kTkVC5yKQqqDwVCSqdy5zw_VxchNAhYpHRMhGH9Y7hUdbc9-A5jM4GhujAwOjbwfgfMLaBT-dCZA-12_spd1tYsX2o3j5k9bqi5eL4D6YZWtvOKDdgIqg7yP8GSMHgbNyFuWu--EqcbU0f-Prol-L2-WldvcjRu-89h7jppis7RRvSukTMkYrsf9Qv6VZSQw</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1668004015</pqid></control><display><type>article</type><title>The B-cell response to a primary and booster course of MenACWY-CRM197vaccine administered at 2, 4 and 12 months of age</title><source>ScienceDirect Journals (5 years ago - present)</source><source>ProQuest Central UK/Ireland</source><creator>Blanchard-Rohner, Geraldine ; Snape, Matthew D ; Kelly, Dominic F ; O'Connor, Daniel ; John, Tessa ; Clutterbuck, Elizabeth A ; Ohene-Kena, Brigitte ; Klinger, Chaam L ; Odrljin, Tatjana ; Pollard, Andrew J</creator><creatorcontrib>Blanchard-Rohner, Geraldine ; Snape, Matthew D ; Kelly, Dominic F ; O'Connor, Daniel ; John, Tessa ; Clutterbuck, Elizabeth A ; Ohene-Kena, Brigitte ; Klinger, Chaam L ; Odrljin, Tatjana ; Pollard, Andrew J</creatorcontrib><description>A quadrivalent meningococcal vaccine conjugated to CRM197(MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197in children. At 5 months of age, following primary immunisation, serogroup-specific memory B-cells were detectable in fewer than 25% of children, although protective antibody titres (hSBA>=4) were detectable in 69% of children against serogroup A and more than 95% against the other serogroups. At 12 months, before booster immunisation the percentages with hSBA>=4 were 5% for serogroup A, and between 44 and 70% for the other serogroups. One month after booster immunisation with MenACWY-CRM197over 50% of children had detectable memory B-cells, and 91% had hSBA>=4 against serogroup A and more than 99% against the other serogroups. These data show that few antigen-specific anticapsular memory B-cells can be detected after two-doses priming with MenACWY-CRM197. For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p<=0.02) but weak correlation with antibody persistence at 12 months. Although previous studies suggest that measuring memory B-cell responses after priming immunisations in infancy can be used to predict antibody persistence and memory responses, this may not be suitable for all antigens in young children.</description><identifier>ISSN: 0264-410X</identifier><identifier>EISSN: 1873-2518</identifier><identifier>DOI: 10.1016/j.vaccine.2013.03.036</identifier><language>eng</language><publisher>Kidlington: Elsevier Limited</publisher><subject>Age ; Biomedical research ; Immunization ; Laboratories ; Meetings ; Meningitis ; Tetanus ; Vaccines ; Whooping cough</subject><ispartof>Vaccine, 2013-05, Vol.31 (20), p.2441</ispartof><rights>Copyright Elsevier Limited May 7, 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/1668004015?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>314,780,784,27923,27924,64384,64388,72240</link.rule.ids></links><search><creatorcontrib>Blanchard-Rohner, Geraldine</creatorcontrib><creatorcontrib>Snape, Matthew D</creatorcontrib><creatorcontrib>Kelly, Dominic F</creatorcontrib><creatorcontrib>O'Connor, Daniel</creatorcontrib><creatorcontrib>John, Tessa</creatorcontrib><creatorcontrib>Clutterbuck, Elizabeth A</creatorcontrib><creatorcontrib>Ohene-Kena, Brigitte</creatorcontrib><creatorcontrib>Klinger, Chaam L</creatorcontrib><creatorcontrib>Odrljin, Tatjana</creatorcontrib><creatorcontrib>Pollard, Andrew J</creatorcontrib><title>The B-cell response to a primary and booster course of MenACWY-CRM197vaccine administered at 2, 4 and 12 months of age</title><title>Vaccine</title><description>A quadrivalent meningococcal vaccine conjugated to CRM197(MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197in children. At 5 months of age, following primary immunisation, serogroup-specific memory B-cells were detectable in fewer than 25% of children, although protective antibody titres (hSBA>=4) were detectable in 69% of children against serogroup A and more than 95% against the other serogroups. At 12 months, before booster immunisation the percentages with hSBA>=4 were 5% for serogroup A, and between 44 and 70% for the other serogroups. One month after booster immunisation with MenACWY-CRM197over 50% of children had detectable memory B-cells, and 91% had hSBA>=4 against serogroup A and more than 99% against the other serogroups. These data show that few antigen-specific anticapsular memory B-cells can be detected after two-doses priming with MenACWY-CRM197. For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p<=0.02) but weak correlation with antibody persistence at 12 months. Although previous studies suggest that measuring memory B-cell responses after priming immunisations in infancy can be used to predict antibody persistence and memory responses, this may not be suitable for all antigens in young children.</description><subject>Age</subject><subject>Biomedical research</subject><subject>Immunization</subject><subject>Laboratories</subject><subject>Meetings</subject><subject>Meningitis</subject><subject>Tetanus</subject><subject>Vaccines</subject><subject>Whooping cough</subject><issn>0264-410X</issn><issn>1873-2518</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>8G5</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>GNUQQ</sourceid><sourceid>GUQSH</sourceid><sourceid>M2O</sourceid><recordid>eNqNjU9LxDAUxIMoWP98BOGBV1PfS9ts96hF8bIXWVBPS2zfui1tUpPsgt_eVvYDCANzmN_MCHFDmBKSvu_Sg6nr1nKqkLIUZ-kTkVC5yKQqqDwVCSqdy5zw_VxchNAhYpHRMhGH9Y7hUdbc9-A5jM4GhujAwOjbwfgfMLaBT-dCZA-12_spd1tYsX2o3j5k9bqi5eL4D6YZWtvOKDdgIqg7yP8GSMHgbNyFuWu--EqcbU0f-Prol-L2-WldvcjRu-89h7jppis7RRvSukTMkYrsf9Qv6VZSQw</recordid><startdate>20130507</startdate><enddate>20130507</enddate><creator>Blanchard-Rohner, Geraldine</creator><creator>Snape, Matthew D</creator><creator>Kelly, Dominic F</creator><creator>O'Connor, Daniel</creator><creator>John, Tessa</creator><creator>Clutterbuck, Elizabeth A</creator><creator>Ohene-Kena, Brigitte</creator><creator>Klinger, Chaam L</creator><creator>Odrljin, Tatjana</creator><creator>Pollard, Andrew J</creator><general>Elsevier Limited</general><scope>3V.</scope><scope>7QL</scope><scope>7RV</scope><scope>7T2</scope><scope>7T5</scope><scope>7U9</scope><scope>7X7</scope><scope>7XB</scope><scope>88C</scope><scope>88E</scope><scope>8AO</scope><scope>8C1</scope><scope>8FE</scope><scope>8FH</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AEUYN</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>C1K</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>K9-</scope><scope>K9.</scope><scope>KB0</scope><scope>LK8</scope><scope>M0R</scope><scope>M0S</scope><scope>M0T</scope><scope>M1P</scope><scope>M2O</scope><scope>M7N</scope><scope>M7P</scope><scope>MBDVC</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>Q9U</scope></search><sort><creationdate>20130507</creationdate><title>The B-cell response to a primary and booster course of MenACWY-CRM197vaccine administered at 2, 4 and 12 months of age</title><author>Blanchard-Rohner, Geraldine ; Snape, Matthew D ; Kelly, Dominic F ; O'Connor, Daniel ; John, Tessa ; Clutterbuck, Elizabeth A ; Ohene-Kena, Brigitte ; Klinger, Chaam L ; Odrljin, Tatjana ; Pollard, Andrew J</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_16680040153</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Age</topic><topic>Biomedical research</topic><topic>Immunization</topic><topic>Laboratories</topic><topic>Meetings</topic><topic>Meningitis</topic><topic>Tetanus</topic><topic>Vaccines</topic><topic>Whooping cough</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Blanchard-Rohner, Geraldine</creatorcontrib><creatorcontrib>Snape, Matthew D</creatorcontrib><creatorcontrib>Kelly, Dominic F</creatorcontrib><creatorcontrib>O'Connor, Daniel</creatorcontrib><creatorcontrib>John, Tessa</creatorcontrib><creatorcontrib>Clutterbuck, Elizabeth A</creatorcontrib><creatorcontrib>Ohene-Kena, Brigitte</creatorcontrib><creatorcontrib>Klinger, Chaam L</creatorcontrib><creatorcontrib>Odrljin, Tatjana</creatorcontrib><creatorcontrib>Pollard, Andrew J</creatorcontrib><collection>ProQuest Central (Corporate)</collection><collection>Bacteriology Abstracts (Microbiology B)</collection><collection>ProQuest Nursing and Allied Health Journals</collection><collection>Health and Safety Science Abstracts (Full archive)</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>ProQuest Health and Medical</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Healthcare Administration Database (Alumni)</collection><collection>Medical Database (Alumni Edition)</collection><collection>ProQuest Pharma Collection</collection><collection>Public Health Database</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest One Sustainability</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>ProQuest Central</collection><collection>Natural Science Collection</collection><collection>Environmental Sciences and Pollution Management</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection</collection><collection>Consumer Health Database (Alumni Edition)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>ProQuest Biological Science Collection</collection><collection>Consumer Health Database</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>ProQuest Health Management</collection><collection>Medical Database</collection><collection>ProQuest Research Library</collection><collection>Algology Mycology and Protozoology Abstracts (Microbiology C)</collection><collection>ProQuest Biological Science Journals</collection><collection>Research Library (Corporate)</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central Basic</collection><jtitle>Vaccine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Blanchard-Rohner, Geraldine</au><au>Snape, Matthew D</au><au>Kelly, Dominic F</au><au>O'Connor, Daniel</au><au>John, Tessa</au><au>Clutterbuck, Elizabeth A</au><au>Ohene-Kena, Brigitte</au><au>Klinger, Chaam L</au><au>Odrljin, Tatjana</au><au>Pollard, Andrew J</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The B-cell response to a primary and booster course of MenACWY-CRM197vaccine administered at 2, 4 and 12 months of age</atitle><jtitle>Vaccine</jtitle><date>2013-05-07</date><risdate>2013</risdate><volume>31</volume><issue>20</issue><spage>2441</spage><pages>2441-</pages><issn>0264-410X</issn><eissn>1873-2518</eissn><abstract>A quadrivalent meningococcal vaccine conjugated to CRM197(MenACWY-CRM197) is immunogenic in young infants. We assessed the memory B-cell and antibody responses after a primary and booster course of MenACWY-CRM197in children. At 5 months of age, following primary immunisation, serogroup-specific memory B-cells were detectable in fewer than 25% of children, although protective antibody titres (hSBA>=4) were detectable in 69% of children against serogroup A and more than 95% against the other serogroups. At 12 months, before booster immunisation the percentages with hSBA>=4 were 5% for serogroup A, and between 44 and 70% for the other serogroups. One month after booster immunisation with MenACWY-CRM197over 50% of children had detectable memory B-cells, and 91% had hSBA>=4 against serogroup A and more than 99% against the other serogroups. These data show that few antigen-specific anticapsular memory B-cells can be detected after two-doses priming with MenACWY-CRM197. For MenC and CRM197, the antigens with the highest number of B-cells at 5 months, there was a definite (p<=0.02) but weak correlation with antibody persistence at 12 months. Although previous studies suggest that measuring memory B-cell responses after priming immunisations in infancy can be used to predict antibody persistence and memory responses, this may not be suitable for all antigens in young children.</abstract><cop>Kidlington</cop><pub>Elsevier Limited</pub><doi>10.1016/j.vaccine.2013.03.036</doi></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0264-410X |
| ispartof | Vaccine, 2013-05, Vol.31 (20), p.2441 |
| issn | 0264-410X 1873-2518 |
| language | eng |
| recordid | cdi_proquest_journals_1668004015 |
| source | ScienceDirect Journals (5 years ago - present); ProQuest Central UK/Ireland |
| subjects | Age Biomedical research Immunization Laboratories Meetings Meningitis Tetanus Vaccines Whooping cough |
| title | The B-cell response to a primary and booster course of MenACWY-CRM197vaccine administered at 2, 4 and 12 months of age |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-10T23%3A41%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20B-cell%20response%20to%20a%20primary%20and%20booster%20course%20of%20MenACWY-CRM197vaccine%20administered%20at%202,%204%20and%2012%20months%20of%20age&rft.jtitle=Vaccine&rft.au=Blanchard-Rohner,%20Geraldine&rft.date=2013-05-07&rft.volume=31&rft.issue=20&rft.spage=2441&rft.pages=2441-&rft.issn=0264-410X&rft.eissn=1873-2518&rft_id=info:doi/10.1016/j.vaccine.2013.03.036&rft_dat=%3Cproquest%3E3641865291%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1668004015&rft_id=info:pmid/&rfr_iscdi=true |